Updated on 7 February 2017
Singapore: In a move to serve customers with ready-to-use solutions for organ-on-a-chip model development and analysis, biotech companies MIMETAS and Molecular Devices will combine marketing efforts on the OrganoPlate organ-on-a-chip platform and ImageXpress Micro Confocal high-content imaging systems.
"OrganoPlates are designed for ease-of-handling at any throughput, and provide unsurpassed physiological relevance," said Jos Joore, Managing Director of MIMETAS.
"As such, they are perfectly suited for the high-content imaging systems from Molecular Devices. We have been using their equipment in our internal R&D with great success. With ready-to-use protocols and methods for OrganoPlates, the ImageXpress Micro portfolio is positioned to fully unleash the potential of OrganoPlates."
At Molecular Devices, Sarah Vargas-Hurlston, Director of Marketing comments, "We are excited to enter into this marketing collaboration with MIMETAS. Their organ-on-a-chip platform has unique capabilities and a proven fit with our ImageXpress Micro systems. At Molecular Devices, we value MIMETAS's approach to offer turnkey solutions to customers which aligns with our continual focus to provide better support for customer applications. Together, we offer a solution with unprecedented capabilities in a rapidly developing organ-on-a-chip market."
MIMETAS is a biotechnology company developing human organ-on-a-chip tissue models for testing drugs, chemicals and food components in OrganoPlates. The company develops and validates customized disease, toxicology and transport models.